Rezum uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE is currently working to respond to the operational challenges posed to our normal work programmes. The stakeholders and advisory committees involved in the development of our guidance include a large number of frontline NHS staff. We know that their priority in this crisis is caring for patients and we do not want to draw them away from this vital work. For this reason, we are reviewing all of our guidance in development and will be prioritising only therapeutically critical topics at this time. Please accept our apologies for any disappointment this may cause. This is a rapidly changing situation and we will keep our approach under review. Our priority is to support the NHS to care for people during this difficult time. At present we’re not able to confirm the key dates for this guidance topic.
Status In progress
Process MT
ID number 413

Project Team

Project lead Ying-ying Wang

Email enquiries


External assessment group Newcastle Upon Tyne Hospitals
Manufacturers Boston Scientific
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Association for Perioperative Practice
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  British Association of Day Surgery
  Royal College of Anaesthetists
  Royal College of Surgeons of England
  The Association for Perioperative Practice
  The College of Operating Department Practitioners
  British Association of Urological Surgeons
Professional groups British Urological Group (BUG)
  PSA Prostate Cancer Support Association


Key events during the development of the guidance:

Date Update
31 March 2020 Expected publication
24 February 2020 Resolution
24 January 2020 Committee meeting: 2
06 December 2019 - 08 January 2020 Draft guidance
15 November 2019 Committee meeting: 1
09 July 2019 Scope published
24 May 2019 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance